Integra Lifesciences Holdings Corp (IART): James M Sullivan , director of Integra Lifesciences Holdings Corp sold 5,260 shares on May 31, 2016. The Insider selling transaction was reported by the company on Jun 2, 2016 to the Securities and Exchange Commission. The shares were sold at $73.82 per share for a total value of $388,293.19 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 11, 2016, John Mooradian (Corp VP, Global Ops & Supp Chn) sold 7,653 shares at $67.04 per share price.On May 11, 2016, Joseph Vinhais (Corp VP,Global Qlty Assurance) sold 972 shares at $73.36 per share price.Also, On May 6, 2016, Glenn Coleman (CVP, CHIEF FINANCIAL OFFICER) sold 3,563 shares at $70.62 per share price.On May 5, 2016, Christian S Schade (director) sold 7,829 shares at $70.42 per share price.
Integra Lifesciences Holdings Corp: On Wednesday, Jun 1, 2016 heightened volatility was witnessed in Integra Lifesciences Holdings Corp which led to swings in the share price. The shares opened for trading at $74.28 and hit $76.23 on the upside , eventually ending the session at $75.82, with a gain of 1.49% or 1.11 points. The heightened volatility saw the trading volume jump to 4,67,469 shares. The 52-week high of the share price is $76.23 and the company has a market cap of $2,822 M . The 52-week low of the share price is at $54.75.
Company has been under the radar of several Street Analysts.Integra Lifesciences Holdings Corp is Reiterated by Barclays to Equal Weight and the brokerage firm has raised the Price Target to $ 74 from a previous price target of $70 .The Rating was issued on Apr 28, 2016.
Integra LifeSciences Holdings Corporation is a medical technology company. The Company offers solutions such as orthopedic extremity surgery neurosurgery spine surgery and reconstructive and general surgery. The Company’s operating segments are: Specialty Surgical Solutions and Orthopedics and Tissue Technologies. The Company’s Specialty Surgical Solutions segment includes the Neurosurgery business and the Instruments business. The Company’s Orthopedics and Tissue Technologies segment includes offerings such as skin and wound repair bone and joint fixation implants in the upper and lower extremities bone grafts and nerve and tendon repair. The Company sources its handheld surgical instruments and specialty metal and pyrocarbon implants through third-party vendors. The Company manufactures its products in plants which are located in the United States Puerto Rico France Germany Ireland and Mexico.